Literature DB >> 29922763

Gastrointestinal endoscopy in patients on direct oral anticoagulants. A consensus paper of the Romanian Society of Gastroenterology and Hepatology.

Andreea Farcas1, Simona Bataga2, Cristina Cijevschi3, Mircea Diculescu4, Daniela Dobru5, Eugen Dumitru6, Adrian Goldis7, Laurentiu Nedelcu8, Alina Popescu7, Ioan Sporea7, Anca Trifan3, Simona Valean9, Cristian Gheorghe10, Dan Lucian Dumitrascu11.   

Abstract

Management of patients undergoing endoscopy and under treatment with the newer direct oral anticoagulants (DOACs) is a common and a complex clinical issue that gastroenterologists have to face more and more often these days. The increasing use of DOACs in patients requiring both short- and long-term anticoagulation is mostly due to the advantages these agents offer, among which the lack of monitoring requirements and the reduced need of dose adjustments are perhaps the most important ones. Managing these patients in the peri-endoscopic period implies balancing the risk for thrombosis that a certain patient carries and the bleeding risk associated with the endoscopic procedure itself. The Romanian Society of Gastroenterology and Hepatology decided to create a consensus paper to serve to practitioners and teachers. After reviewing the available published data and existing recommendations, a Delphi consensus process was carried out involving the leaders of opinion in this field. After reaching expert consensus, we provide herein guidance for a practical approach of DOACs therapy management in patients with endoscopic interventions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29922763     DOI: 10.15403/jgld.2014.1121.272.end

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  1 in total

1.  Treatment of Acute Nonvariceal Upper Gastrointestinal Bleeding in Chinese Patients on Antithrombotic Therapy.

Authors:  Feng Gao; Xue Chen; Jie Zhang
Journal:  Gastroenterol Res Pract       Date:  2019-12-18       Impact factor: 2.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.